87 completed. 87 Phase 2, 9 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 87 | Completed 87 |
| Phase 1 | 9 | Completed 9 |
| Phase 3 | 6 | Completed 6 |
Follow Alopecia: new trials by email Literature Review of Alopecia trials Research Report on Alopecia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s), PRP-only injection into the alopecic area - Androgenetic Alopecia (AGA) | Phase 2 | Completed | Nanfang Hospital, Southern Medical University | 83 | 2026-01-09 | 2026-09-09 |
| Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia minoxidil + finasteride, Placebo foam - Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA) | Phase 2 | Completed | Beijing Dayspring Pharmaceutical Technology Co., Ltd | 110 | 2024-12-05 | 2026-03-03 |
| Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent Baricitinib - Central Centrifugal Cicatricial Alopecia | Phase 2 | Completed | Raven Clinical Research | 27 | 2024-10-22 | 2026-09-28 |
| Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA PP405 0.05% Topical Gel, Topical Vehicle Gel - Androgenetic Alopecia | Phase 2 | Completed | Pelage Pharmaceuticals, Inc. | 78 | 2024-06-05 | 2026-10-21 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) Rezpegaldesleukin, Placebo - Alopecia Areata | Phase 2 | Completed | Nektar Therapeutics | 94 | 2024-04-02 | 2026-09-18 |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants IMG-007 - Alopecia Areata (AA) | Phase 1 / Phase 2 | Completed | Inmagene LLC | 29 | 2023-09-25 | 2026-02-09 |
| Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%), Platelet Rich Plasma - Androgenetic Alopecia | Phase 2 | Completed | Services Hospital, Lahore | 30 | 2023-09-21 | 2024-10-22 |
| A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia placebo-Q2W, HMI-115-120mg-Q4W, HMI-115-240mg-Q4W - Androgenetic Alopecia | Phase 2 | Completed | Hope Medicine (Nanjing) Co., Ltd | 192 | 2023-09-11 | 2025-06-04 |
| Effectiveness of Apheresis Platelet-Rich Plasma Injection for Androgenic Alopecia Autologous Apheresis PRP Injection - Androgenic Alopecia | Phase 2 | Completed | zhang li | 201 | 2023-09-01 | 2026-01-20 |
| To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males GT20029 Tincture, GT20029 matching placebo - Alopecia, Male Pattern Hair Loss | Phase 2 | Completed | Suzhou Kintor Pharmaceutical Inc, | 180 | 2023-04-13 | 2024-11-18 |
| Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution - Alopecia, Androgenetic | Phase 2 | Completed | Technoderma Medicines Inc. | 71 | 2023-03-06 | 2025-11-12 |
| To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata Azathioprine (AZA), Betamethasone - Alopecia Areata, Alopecia Areata(AA) | Phase 2 | Completed | Sheikh Zayed Medical College | 60 | 2023-03-01 | 2025-01-22 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3 - Androgenetic Alopecia | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 121 | 2022-12-20 | 2024-06-28 |
| Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata EQ101 - Alopecia Areata, Alopecia | Phase 2 | Completed | Equillium | 36 | 2022-12-19 | 2025-04-10 |
| Ritlecitinib for Cicatricial Alopecia PF-06651600 - Cicatricial Alopecia | Phase 2 | Completed | Emma Guttman | 50 | 2022-12-15 | 2026-07-15 |
| Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men prostaglandin F2a analogue in vehicle solution high dose, prostaglandin F2a analogue in vehicle solution low dose, active ingredient-free vehicle solution to DLQ01 - Androgenetic Alopecia | Phase 1 / Phase 2 | Completed | Dermaliq Therapeutics, Inc. | 120 | 2022-12-05 | 2024-04-08 |
| Activated PRP for Treatment of Androgenetic Alopecia Autologous platelet-rich plasma - Androgenetic Alopecia | Phase 1 / Phase 2 | Completed | Santiste Medical Inc. | 17 | 2022-05-17 | 2025-04-27 |
| Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata Daxdilimab - Alopecia Areata | Phase 2 | Completed | Amgen | 30 | 2022-04-27 | 2025-01-07 |
| A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA) STS01, Placebo - Alopecia Areata | Phase 2 | Completed | Soterios Ltd | 158 | 2022-03-23 | 2024-05-07 |
| To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826 - Alopecia, Male Pattern Hair Loss | Phase 2 | Completed | Suzhou Kintor Pharmaceutical Inc, | 123 | 2022-01-31 | 2023-11-22 |
Showing 20 of 87. Sign in to see all of them.
Alopecia Areata (31) · Alopecia universalis (8) · Skin Diseases (2) · Autoimmune Diseases (1) · Breast Neoplasms (1) · Dermatitis, Atopic (1) · Down Syndrome (1) · Eczema (1) · Hair Diseases (1) · Hidradenitis Suppurativa (1) · Hirsutism (1) · Hypertrichosis (1) · Immune System Diseases (1) · Inflammation (1)
Hypotrichosis (87) · Skin and Connective Tissue Diseases (87) · Hair Diseases (86) · Skin Diseases (85) · Pathological Conditions, Signs and Symptoms (65) · Pathological Conditions, Anatomical (64) · Immune System Diseases (2) · Neoplasms (2) · Skin Diseases, Papulosquamous (2) · Abnormalities, Multiple (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Breast Diseases (1) · Chromosome Disorders (1)
Minoxidil (10) · Solutions (5) · Bimatoprost (3) · Finasteride (3) · PF-06651600 (2) · PF-06700841 (2) · Triamcinolone (2) · baricitinib (2) · tofacitinib (2) · 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido(4,3-b)indol-5(2H)-yl)acetic acid (1) · Abatacept (1) · Administration, Oral (1) · Azathioprine (1) · BID protein, human (1) · Betamethasone (1)
Aderans Research Institute (11) · Allergan (4) · Concert Pharmaceuticals (4) · Aclaris Therapeutics, Inc. (3) · Biosplice Therapeutics, Inc. (3) · Columbia University (3) · Emma Guttman (3) · Follicum AB (3) · Pfizer (3) · Suzhou Kintor Pharmaceutical Inc, (3) · Legacy Healthcare SA (2) · University of Minnesota (2) · Yale University (2) · Ahmed Hassan Nouh MD (1) · Amgen (1)
United States (53) · China (10) · Germany (9) · Canada (8) · Australia (6) · South Korea (5) · Egypt (2) · Japan (2) · Mexico (2) · Pakistan (2) · Poland (2) · Russia (2) · Spain (2) · Taiwan (2) · United Kingdom (2)
Julian Mackay-Wiggan, MD, MS (3) · Yusuf Yazici, M.D. (3) · Emma Guttman, MD, PhD (2) · Ulrike Blume-Peytavi, Professor (2) · Alina Abbass, MBBS, FCPS (1) · Alison Bruce, M.B. Ch.B (1) · Anthony Andrasfay (1) · Betsy Hughes-Formella, PhD (1) · Brett King, MD (1) · Brett King, MD, PhD (1) · Brian Freund, MD (1) · ChangHun Huh, MD, PhD. (1)
PMID 37917289, PMID 38263353, PMID 41917311, PMID 42481842, PMID 19620039, PMID 20115946, PMID 21042071, PMID 21199096, PMID 21712909, PMID 21899919, PMID 25601618, PMID 25676427, PMID 25765294, PMID 27699252, PMID 27699253, PMID 28619556, PMID 29452121, PMID 29923063, PMID 30113844, PMID 31245963, PMID 31321800, PMID 31574029, PMID 32478930, PMID 34460948, PMID 34863853, PMID 34915057, PMID 35334197, PMID 36045513, PMID 36571611, PMID 36763878, PMID 36855020, PMID 37062298, PMID 37381691, PMID 37403610, PMID 37556146, PMID 37707764, PMID 37991697, PMID 38833144, PMID 38904749, PMID 38946973, PMID 39141364, PMID 39254890, PMID 39328096, PMID 39441519, PMID 39461505, PMID 39575597, PMID 39737640, PMID 39962358, PMID 40145547, PMID 40214720
2016 (1), 2017 (1), 2018 (1), 2023 (1), R33AR077495 (1)